Research Article

Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy

Charles E. Rengifo,1 Rancés Blanco,2 Damián Blanco,3 Mercedes Cedeño,2 Milagros Frómeta,2 and Enrique Rengifo Calzado2

1 Department of Pathology, Manuel Fajardo General Hospital, 10400 Havana, Cuba
2 Laboratory of Recognition and Biological Activity Assays, Department of Quality Control, Center of Molecular Immunology, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba
3 Department of Cell Biology and Tissues Banking, National Institute of Oncology and Radiobiology, 10400 Havana, Cuba

Correspondence should be addressed to Enrique Rengifo Calzado; rengifo@cim.sld.cu

Received 30 August 2012; Revised 13 November 2012; Accepted 14 November 2012

Adequate methods to identify which lung cancer patients are most likely to benefit from the targeted drugs against both epidermal growth factor receptor/epidermal growth factor (EGFR/EGF) are needed. For this reason, we evaluated both the tissue reactivity of ior egfr/r3 monoclonal antibody (Mab) in human lung carcinomas and its biological activity in NCI-H125 cells. Additionally, we assessed the tissue expression of EGF using two Mabs, CB-EGF1 and CB-EGF2. The overexpression of EGFR was detected in 33.33% and 62.71% of small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), respectively. The ability of ior egfr/r3 Mab to bind the extracellular domain of EGFR inhibiting cell proliferation and inducing apoptosis in NCI-H125 cells was also demonstrated. The EGF expression was observed in about 17% and 70% of SCLC and NSCLC, respectively. However, differences in the reactivity of CB-EGF1 and CB-EGF2 were evidenced. A dual expression of EGFR and EGF was observed in 16.67% and 57.63% of SCLC and NSCLC patients, respectively. But, a correlation between them was only obtained in NSCLC. Our results permit to recommend the development of diagnostic kits using ior egfr/r3 and/or CB-EGF1 Mabs in order to achieve a better selection of patients to EGFR/EGF-targeting treatment.

1. Introduction

Lung cancer is one of the leading causes of cancer-related deaths worldwide [1]. Non-small-cell lung cancer (NSCLC) is the most common form of the disease, accounting for approximately 85% of all cases [2]. In patients with NSCLC, some genetic and regulatory abnormalities have been considered responsible for the tumor survival advantage [3], limiting the survival benefit provided by the standard therapeutic options available. Therefore, drugs targeting abnormal pathways could lead to more effective treatments for this often difficult disease [4].

Since the identification of some alterations in the expression of both epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) in lung cancer pathogenesis, several therapeutic targeting agents have been employed for the treatment of lung tumors overexpressing these molecules [5, 6].

At least three different types of agent for EGF/EGFR inhibition are currently in use: tyrosine kinase inhibitors (TKIs), monoclonal antibodies (Mabs), and molecular cancer vaccines. Among them, nimotuzumab, a humanized therapeutic monoclonal antibody that neutralize the EGFR, and CIMAVax-EGF, a molecular vaccine that induces anti-EGF
antibodies neutralizing endogenous EGF, have demonstrated promising results in patients with NSCLC, alone or combined with established modalities [5–7].

Nevertheless, methods to identify which patients are most likely to benefit from these targeted drugs are needed. In this way, the application of adequate immunohistochemical methods could permit a better evaluation of these molecules leading patients to a more appropriate therapeutic strategy. To date, one of the most explored pretreatment biomarkers is the status of the target molecules.

For these reasons, in this work we evaluated the tissue reactivity of ior egf/r3 Mab, the murine counterpart of nimotuzumab [8], in lung carcinomas as well as, the ability of this Mab to bind the extracellular domain of EGFR inhibiting cell proliferation and inducing apoptosis in a NSCLC cell line. Additionally, we assessed the tissue expression of EGF ligand using two different Mabs: CB-EGF1 and CB-EGF2 [9].

2. Materials and Methods

2.1. Tissue Specimens and Previous Processing. A number of 71 routinely processed, formalin-fixed, and paraffin-embedded archival samples with diagnosis of lung cancer were obtained from the pathology department of the National Institute of Oncology and Radiobiology. The samples were taken after obtaining the approval consent by the institutional ethical committee. Five microns serial sections from each block were obtained in a Litz 1512 micrometer and mounted on plus slides (Dako S2024, Carpinteria, USA). All sections were attached to the slide by heating in a 60°C oven for 1 h. Afterward the slides were kept at room temperature and they were used within 30 days.

The slides were dewaxed in xylene and rehydrated in decreasing ethanol series as usual and endogenous peroxidase activity was blocked with 0.03% hydrogen peroxide in methanol for 30 minutes at room temperature. Afterward all sections were washed in distilled water for 10 minutes and then were rinsed with TBS (Tris/saline buffer solution) for 5 minutes.

2.2. Immunohistochemical Staining. In order to verify the quality of the formalin-fixed and paraffin-embedded tissues a monoclonal antibody that detects an epitope common to many cytokeratin (clone MN-116, Dako M0821, Carpinteria, USA) was used. The slides were pretreated with 10 mM sodium citrate buffer at pH 6.0 for 10 minutes in a microwave oven at 600 W. The rest of sections were placed in a humid chamber and pretreated with 0.4% pepsin in 0.1N hydrochloric acid solution at 37°C for 30 minutes. After pretreatments, the slides were washed gently in tap water and then with distilled water and TBS, as were described above.

The samples were incubated with the primary mouse ior egf/r3 (anti-EGFR), CB-EGF1, CB-EGF2 (anti-EGF), and MN-116 Mabs for 1 h at room temperature. Negative controls were performed by substituting primary antibody for TBS and sections of colonic adenocarcinoma of known positivity for these antigens were taken as positive control. After two rinses in TBS the slides were incubated with a rabbit anti-mouse biotinylated secondary antibody (Dako E0354, Carpinteria, USA) and ABComplex/HRP (Dako E0355, Carpinteria, USA) both for 30 minutes at room temperature dilution 1:100. Between incubations, slides were washed with TBS for 10 minutes. Afterward, enzymatic activity was visualized with DAB substrate chromogenic solution (Dako K3465, Carpinteria, USA) and the tissues were counterstained with Mayer’s Hematoxylin (Dako S2020, Carpinteria, USA). The samples were dehydrated and mounted with a synthetic medium.

2.3. Immunohistochemical Evaluation. The IHC score (H-score) was used as was previously described [10]. Briefly, all markers were evaluated for percentage of positive cells (0–100%) and the intensity of reaction (0–3+). The results in agreement with two observers (ChER and RB) were considered as final. Afterward, the H-score was calculated for each specimen by multiplication of the intensity of reaction and the grade of positive cells, resulting in a score ranging from 0 to 300. Subsequently, these scores were grouped as follow: 0 (score 0); 1 (scores < 150); 2 (scores ≥ 150).

2.4. Pathological Features Evaluation. Some morphological parameters such as histopathological classification, grade of differentiation, degree of cellular pleomorphism, and mitotic and necrosis indexes were evaluated for an expert pathologist (ChER) in each tumor tissue using hematoxylin and eosin (H/E) staining.

The degree of cell pleomorphism was evaluated considering some cytomorphologic characteristics such as cell and nuclear size, cellular shape, chromatin pattern, nucleoli, and amount of cytoplasm, and was scored as follows: 0 (no evident cell pleomorphism), 1 (low), 2 (moderate), and 3 (high) cell pleomorphism. Mitotic activity index (MAI) was recorded by the evaluation of 10 high-power fields with 400x magnification (10x ocular, 40x objective) in the most cellular area of the tumor (containing the subjectively highest number of mitoses) [11]. Only unequivocal mitotic figures were counted. Finally, the MAI was calculated by dividing cells out of total cells counted and expressed as previously described for cell pleomorphism. For the evaluation of the degree of tumor necrosis (necrosis index) on each section a low-power field with 100x magnification (10x ocular, 10x objective) was used. It was scored subjectively as follows: 0 (no necrosis), 1 (less than 50% of necrosis areas per field), and 2 (more than 50% of necrosis areas per field).

2.5. Cells Line and Culture. A human non-small-cell lung cancer NCI-H125 (ATCC CRL-5801) cell line was kindly provided by the research direction (Center of Molecular Immunology). Cells were grown in Dulbecco’s modified Eagle’s media (12800-017, GIBCO Invitrogen Co., USA) supplemented with 5% heat-inactivated fetal bovine serum (100082, GIBCO Invitrogen Co., USA). Cells were maintained at 37°C in a humidified atmosphere of air containing 5% CO₂ and were harvested using a trypsin-EDTA solution (T-3924, SIGMA-ALDRICH Co. St. Louis, MO, USA).
2.6. Inhibition of Cell Proliferation and Apoptosis Measurement. Cells were seeded in a 6-well cell culture dishes at a density of 100,000 cells/well, in culture medium containing 5% FBS, and incubated at 37°C and 5% CO₂. Twenty four hours later, the medium was changed to 1% FBS for serum starvation, and cells were exposed to different concentrations (12.5, 25, 50, 100, and 200 μg/mL) of the murine anti-EGFR antibody ior egf/r3 for 96 h. An irrelevant Mab was used as negative control (T1h Mab raised against CD6). Also, additional doses of each antibody were added when freshly medium was replaced according to the following experimental design: treatment 1 (no additional dose), treatment 2 (one additional dose after 48 h), and treatment 3 (additional doses every day). The cells were harvested by trypsinization, washed and resuspended in 0.5 mL FACSFlow (additional doses every day). The cells were harvested by trypsinization, washed and resuspended in 0.5 mL FACSFlow (Becton-Dickinson, USA). Afterward, cells were incubated for 30 minutes with 0.5 mL of cold absolute ethanol (HS002-97003, Spectrum Chemical MFG Co., USA) at 4°C. A further incubation was performed with 1 mL of propidium iodide/RNaseA solution for at least 30 minutes at room temperature. The percentage of cells in sub-G0-G1, G0-G1, S, and G2-M phases was analyzed using a FACSScan flow cytometer (Becton-Dickinson, San Jose, CA, USA) equipped with a doublet discrimination module (DDM), CellQuest software (version 2.0) and ModFit LT (Verity Software House, version 2.0), respectively. To determine the apoptotic population, the sub-G0-G1 peak was also measured. Each experiment was repeated at least twice on different days using different subcultures of NCI-H125 cell line.

2.7. Statistical Analysis. GraphPad Prism 5 software (2007 GraphPad Software Inc. La Jolla, CA, USA) was used for data analysis. The correlation between the reactivity of CB-EGF1 and CB-EGF2 Mabs was assessed by Spearman ranks correlation coefficients. Survival distribution was estimated by the Kaplan-Meier method. Survival comparison was performed by two-sided log-rank tests. The percent of cells in sub-G0-G1, G0-G1, S, and G2-M phases of the cell cycle according to the experimental design was compared using Two-way ANOVA followed by Bonferroni post hoc test. For all tests, \( P < 0.05 \) was considered statistically significant. The percent of cell growth inhibition was calculated using the average of cell of cell growth in the following formula: % of cell growth inhibition = (control sample – treatment sample)/control sample \( \times 100 \).

3. Results

3.1. Patient Description and Pathological Features. Tables 1 and 2 showed a summary of patient characteristics and some pathological features. The median patient age at presentation was 55.65 years ( ranged from 23 to 86 years). Median overall survival of the population was 25.52 months ( ranged from 0.93 to 57.17) for SCLC, 30.16 months ( ranged from 0.70 to 40.57) for patients with stage I, II, or IIIA NSCLC, and 18.86 months for patients with stage IIIB or IV NSCLC. The stage was found to be associated with the overall survival of NSCLC patients \( (P = 0.0405; \ Log \ rank \ test) \) (Figure 1).

3.2. EGF Receptor Was Mainly Expressed in NSCLC but No Correlation with Survival Was Observed. The tissues showed a good morphology, preserving undamaged the molecular antigenic determinants by means of the immunoreactivity of the monoclonal antibody against cytokeratin. No correlation between the EGFR expression and the overall survival of NSCLC patients was observed \( (P = 0.9560; \ Log \ rank \ test) \) (Figure 2) neither with tumor and patient characteristics (data not shown). Nevertheless, a statistically significant difference was obtained when the overexpression of EGFR in stage I–IIIA and IIIB–IV was compared \( (P = 0.0264; \ Chi-square \ test) \). The pattern of staining of ior egf/r3 Mab was finely granular and was mainly located in the plasmatic membrane of malignant cells, although their cytoplasm was also decorated (Figures 3(a) and 3(b)). The reactivity of ior egf/r3 Mab was evidenced in 37/59 (62.71%) of NSCLC samples. According to the histopathological classification, 11/20 (55.00%) squamous cell carcinoma, 13/23 (56.52%) adenocarcinoma, 5/6 (83.33%) large cell carcinoma, and 8/10 (80.00%) of other minor types represented were recognized by the ior egf/r3 (Table 3). The expression of EGFR was also evidenced in 4/12 (33.33%) of SCLC.

| Features | No. (%) |
|----------|---------|
| Gender  |         |
| Female  | 23/71 (32.39) |
| Male    | 48/71 (67.61) |
| Age (years) |     |
| <60      | 52/71 (73.24) |
| 60–70    | 14/71 (19.72) |
| >70      | 5/71 (7.04)  |
| Tumor size (cm) | |
| <3       | 27/71 (38.03) |
| >3       | 44/71 (61.97) |
| Tumor stage |     |
| Small cell lung carcinoma | |
| LD       | 10/12 (83.33) |
| I        | 2/12 (16.66)  |
| Non-small cell lung carcinoma | |
| LD       | 2/59 (3.39)  |
| I        | 38/59 (64.41) |
| II       | 7/59 (11.86)  |
| IIIA     | 4/59 (6.78)   |
| IIIB     | 2/59 (3.39)  |
| IV       | 6/59 (10.17)  |
| Recurrence |       |
| Yes      | 58/71 (81.69) |
| No       | 13/71 (18.31) |
| Overall survival |    |
| Life     | 44/71 (61.97) |
| Death    | 27/71 (38.03) |

No.: number of cases; %: percentages; LD: limited disease.
Table 2: Tumor characteristic.

| Features                        | No. (%)       |
|---------------------------------|---------------|
| **Histopathological type**      |               |
| Small cell lung carcinoma       | 12/71 (16.90) |
| Non-small cell lung carcinoma   |               |
| Squamous cell carcinoma         | 20/71 (28.17) |
| Adenocarcinoma                  | 23/71 (32.39) |
| Large cell carcinoma            | 6/71 (8.45)   |
| Other                           | 10/71 (14.08) |
| **Grade of differentiation**    |               |
| Well                            | 10/71 (14.08) |
| Moderate                        | 24/71 (33.80) |
| Poor                            | 22/71 (30.99) |
| Undifferentiated                | 15/71 (21.13) |
| **Degree of cell pleomorphism** |               |
| No evident                      | 3/71 (4.22)   |
| Low                             | 29/71 (40.85) |
| Moderate                        | 23/71 (32.39) |
| High                            | 16/71 (22.53) |
| **Necrosis index**              |               |
| No evident                      | 27/71 (38.03) |
| < 50%                           | 17/71 (23.94) |
| > 50%                           | 27/71 (38.03) |
| **Mitotic index**               |               |
| No evident                      | 8/71 (11.27)  |
| Low                             | 22/71 (30.99) |
| Moderate                        | 22/71 (30.99) |
| High                            | 19/71 (26.76) |

No.: number of cases; %: percentages.

3.3. Expression of EGF Was Also Detected in Lung Tumors although Differences in the Reactivity of the Anti-EGF Mabs Were Evidenced. We used two different anti-EGF ligand monoclonal antibodies (kindly provided by the Center for Genetic Engineering and Biotechnology, Havana, Cuba). The percent of positive cases according to the histopathological classification of the tumors is extensively described in Table 4. The pattern of staining of these Mabs was finely granular and mainly located in cytoplasm, although a membrane staining was also observed. In addition, an extracellular pattern of staining was detected (Figures 3(c) and 3(d)). A slight increase in the intensity of reaction was observed with CB-EGF1 Mab. Noteworthy, a significant correlation was detected when the reactivity of CB-EGF1 and CB-EGF2 Mabs were compared ($P < 0.0001, rs = 0.5429$; Spearman test). However, no correlation between the EGF expression and the overall survival of patients was observed for both CB-EGF1 and CB-EGF2 Mabs ($P = 0.9144$ and $P = 0.2706$; Log rank test, resp.). No differences were also evidenced when the reactivity of both CB-EGF1 and CB-EGF2 Mabs were compared in stage I–IIIA and IIIB–IV ($P = 0.8154$ and $P = 0.2743$; Chi-square test, resp.).

3.4. The Dual Expression of Both EGFR and EGF Correlated in NSCLC but Not in SCLC. The dual expression of both EGFR and EGF was observed in 2/12 (16.67%) and 34/59 (57.63%) of SCLC and NSCLC, respectively. A significant correlation was detected when the expression of EGFR was compared with the reactivity of CB-EGF1 Mab in NSCLC samples but not in SCLC ($P = 0.0006, rs = 0.4319$ and $P = 0.3784, rs = −0.2798$, respectively; Spearman test). Similar results were obtained with CB-EGF2 Mab ($P = 0.0035$, $rs = 0.3740$ and $P = 0.5918$, $rs = −0.1725$; Spearman test). Additionally, no correlation between the dual expression of both EGFR and EGF with tumor and patient characteristics was obtained (data not shown) neither with the overall survival of NSCLC patients ($P = 0.7321$ and $P = 0.9235$; Log rank test).
TABLE 3: Immunohistochemical expression of EGF receptor.

| Histopathological type        | 0     | 1     | 2     |
|-------------------------------|-------|-------|-------|
|                               | No. (%) | No. (%) | No. (%) |
| SCLC                          | 8/12 (66.67) | 3/12 (25.00) | 1/12 (8.33) |
| NSCLC                         |        |       |       |
| Squamous cell carcinoma       | 9/20 (45.00) | 6/20 (30.00) | 5/20 (25.00) |
| Adenocarcinoma                | 10/23 (43.48) | 7/23 (30.43) | 6/23 (26.09) |
| Large cell carcinoma          | 1/6 (16.67) | 3/6 (50.00) | 2/6 (33.33) |
| Other                         | 2/10 (20.00) | 4/10 (40.00) | 4/100 (4.00) |

SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; No.: number of cases; %: percentages; 0: negative; 1: scores < 150; 2: scores ≥ 150.

3.5. Inhibition of NCI-H125 Cell Proliferation and Apoptosis Induction Was Time and Dose-Dependent. We evaluated the ability of ior egf/r3 Mab to mediate specific biological functions such as cell growth inhibition and induction of apoptosis in a non-small-cell lung cancer cell line. Growth curve profiles were evaluated in NCI-H125 following the addition of different antibody concentrations of ior egf/r3 (12.5, 25, 50, 100 and 200 µg/mL) in a period of 48, 72 and 96 h. No differences in the inhibition of cell proliferation were detected after 48 and 72 h (data not shown). The percent of inhibition ranged from 50.30 to 65.64% (S phase) as compared to the irrelevant control, obtaining the maximum of cell growth inhibition at 100 µg/mL (Figure 4(a)). No induction of apoptosis was observed with this experimental design (sub G0-G1 peak, $P = 0.3062$; ANOVA).

To investigate whether the biological activity of ior egf/r3 is dose-dependent, additional doses of Mabs were added when freshly medium was replaced. This growth inhibition profile is showed in Figure 4(b). The addition of ior egf/r3 caused a significant inhibition on cell proliferation 48 h after Mab was added to the culture (treatment 2) (S phase, $P = 0.0015$; ANOVA), reaching the maximal inhibition at 96 h (treatment 3) (S phase, $P = 0.0053$; ANOVA), as compared to the treatment 1 (S phase, $P = 0.0149$; ANOVA) used as control. The exposure to ior egf/r3 Mab caused a more marked inhibition on proliferation in a dose-dependent
### Table 4: Immunolocalization of EGF ligand using 2 different monoclonal antibodies.

| Histopathological type          | 0 No. (%) | 1 No. (%) | 2 No. (%) |
|---------------------------------|-----------|-----------|-----------|
| SCLC                            |           |           |           |
| CB-EGF1                         | 2/12 (16.67) | 6/12 (50.00) | 4/12 (33.33) |
| CB-EGF2                         | 5/12 (41.67) | 5/12 (41.67) | 2/12 (16.67) |
| NSCLC                           |           |           |           |
| Squamous cell carcinoma         |           |           |           |
| CB-EGF1                         | 3/20 (15.00) | 12/20 (60.00) | 5/20 (25.00) |
| CB-EGF2                         | 6/20 (30.00) | 13/20 (65.00) | 1/20 (5.00) |
| Adenocarcinoma                  |           |           |           |
| CB-EGF1                         | 5/23 (21.74) | 9/23 (39.13) | 9/23 (39.13) |
| CB-EGF2                         | 8/23 (34.78) | 10/23 (43.48) | 5/23 (21.74) |
| Large cell carcinoma            |           |           |           |
| CB-EGF1                         | 1/6 (16.67) | 2/6 (33.33)  | 3/6 (50.00) |
| CB-EGF2                         | 0/6 (00.00) | 3/6 (50.00)  | 3/6 (50.00) |
| Other                           |           |           |           |
| CB-EGF1                         | 3/10 (30.00) | 1/10 (10.00) | 6/10 (60.00) |
| CB-EGF2                         | 4/10 (40.00) | 3/10 (30.00) | 3/10 (30.00) |

SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; No.: number of cases; %: percentages; 0: negative; 1: scores < 150; 2: scores ≥ 150.

manner. Curiously, after 96h of incubation and adding additional doses of ior egfr/r3 Mab (treatment 3), an increase in the percentage of cells undergoing apoptosis was obtained as compared to the irrelevant Mab (sub-G0-G1 peak, $P = 0.0290$; ANOVA) (Figures 4(c) and 4(d)).

### 4. Discussion

Up to date, TNM staging system (Tumor, Node, Metastasis) after surgery is considered the most important prognostic factor in NSCLC [12, 13]. TNM staging system also leads the clinicians to the selection of a more appropriate conventional treatment (e.g., surgery, radiation, chemotherapy) for NSCLC patients. In this study, we showed an increased overall survival of patients at stages I–IIIA as compared with the group of patients at stages IIIB–IV. It is known, the prognosis of patients at stages IIIB–IV NSCLC is poor due to the effectiveness of the conventional modalities of treatment.

Therefore, the application of newer treatment modalities in order to improve patient survival and overall quality of life is mandatory [12, 13]. Consequently, in the last years the EGFR pathway inhibition has been accepted as an option for the first-, second- and third-line therapy of NSCLC [14].

In NSCLC, the overexpression of EGFR has been reported to be ranging from 40% to 89% [15, 16]. Here, we obtained the overexpression of EGFR in about 62% of NSCLC using the ior egfr/r3 Mab. The ability of ior egfr/r3 Mab to recognize human EGFR in frozen lung carcinoma tissues by immunohistochemistry was previously reported [17]. Moreover, the efficacy of the 99mTc-labeled ior egfr/r3 Mab for the detection of epithelial-derived tumors, their metastases and recurrences by radioimmunoscintigraphy was previously evaluated [18]. In addition, no correlation between the expression of EGFR and the overall survival of patients was observed. The overexpression of EGFR has been associated with a more aggressive disease and reduced survival in a variety of tumors types [19], but in NSCLC the evidences are less convincing [20].

Additionally, we showed that blocking EGF binding to the receptor, in a NSCLC-derived cell line (NCI-H125) by means of ior egfr/r3 significantly decreased tumor cell proliferation and induced apoptosis. The ior egfr/r3 Mab recognizes an epitope located in the extracellular domain of the human EGFR with high affinity [21]. Nevertheless, it is known that therapy with murine-derived Mabs is limited by their tendency to develop human anti-mouse antibodies response (HAMA) [22]. For this reason, a humanized therapeutic version of ior egfr/r3 Mab (nimotuzumab) was developed in our center [8]. In clinical trials, nimotuzumab has exhibited promising results used as a sensitizer to radio- or chemotherapy in advanced NSCLC patients positive for EGFR expression [23, 24].

Usually, the selection of patients to any anti-EGFR therapy using a neutralizing Mab is based on the tissue reactivity of a different anti-EGFR Mab for diagnostic purposes. On the contrary, nimotuzumab was obtained by transplanting the complementary determining regions (CDRs) of the ior egfr/r3 Mab to a human framework [8]. Nimotuzumab and egfr/r3 showed a very similar immunohistochemical pattern of recognition of fetal, adult and some malignant tissues, including SCLC and NSCLC [17]. In this way, the evaluation of EGFR expression by IHC using the ior egfr/r3 Mab could provide more specific information in the selection of NSCLC patients to nimotuzumab treatment.

In a previous report, EGFR was significantly more expressed in stage IIIA when compared to earlier stages (I-II) [25], suggesting that expression increases stepwise from precancerous lesions to more advanced stages of cancer [26].
Nevertheless, in this work, patients at stage I–IIIA displayed higher level of EGFR expression as compared with those at stages IIIB–IV. Interestingly, we obtained a significant correlation when the expression of EGFR and EGF was compared, although, no differences in the expression of EGF between NSCLC stages were evidenced. It is known, the upregulation of EGFR expression by EGF is considered a mechanism that promotes the development and progression of tumors [27].

Our results permit to suggest a major activation state of the EGF/EGFR system in earlier stage of the disease, due to EGFR is mainly activated by the binding of its ligands. In line with this, some authors have suggested that growth factor/receptor loop is more important for lung tumor formation than for tumor progression [28, 29]. Notoriously, the dual expression of EGFR and EGF was observed in about 60% of NSCLC patients. In this way, our data also support the potential use of combined passive and active immunotherapy in tumors overexpressing both molecules, not depending of the stage of the disease.

On the other hand, the identification of deregulated expression of EGF family ligands in lung cancer pathogenesis

Figure 4: Antiproliferative activity of ior egf/r3 Mab in cultures of NCI-H125 cells. (a) Known numbers of NCI-H125 cells were treated with the indicated concentrations of anti-EGFR Mab and cultured for 72 h. The maximum of cell growth inhibition was obtained at 100 μg/mL. Data points, means of triplicate samples; bars, SE. (b) Cells cultures were incubated for 72 with ior egf/r3 Mab at 100 μg/mL following 3 different treatment designs (Materials and Methods). See: The statistical significant differences between treatment 1 and 3 (S phase, 0.0149; ANOVA). (c) and (d) Representative flow cytometry histograms of the NCI-H125 cells treated with the irrelevant Mab and with ior egf/r3 Mab, respectively. (d) Note an increase in the percentage of cells undergoing apoptosis (area in gray color) as well as the decrease in the percentage of cells in S phase (area in blue color).
has permitted to consider their potential use as therapeutic targeting agents [30]. Here, we found the tissue overexpression of EGF in at least the 70% of NSCLC samples, although no correlation between the EGF expression and the overall survival of patients was obtained. In a previous report, both increased levels of serum EGF as well as increased reactivity to EGF were found in NSCLC patients. Nevertheless, a correlation of higher level of serum EGF and poorly overall survival of patients was evidenced [6].

Nevertheless, we obtained statistical significant differences when reactivity of CB-EGF1 and CB-EGF2 Mabs were compared. In a previous report using competition assays, it was demonstrated that CB-EGF1 and CB-EGF2 bind to different antigenic determinants of EGF. In addition, differences in the specificity of these Mabs have been reported. While CB-EGF1 is a highly specific Mab to human EGF, the CB-EGF2 Mab also reacts with the murine EGF [9]. These results could support the major reactivity of CB-EGF1 Mab evidenced in our study. Interestingly, an increasing in the overall survival of advanced NSCLC patients treated with CIMAVax-EGF has been reported [6, 7]. In this way, the evaluation of EGF expression on both serum and tumor section using the CB-EGF1 Mab could lead to a better selection of NSCLC patients to CIMAVax-EGF therapy.

Finally, the EGFR is commonly overexpressed in NSCLC, but is rare in SCLC [15, 31, 32]. In our study, we obtained the overexpression of EGFR in about 33% of SCLC. By the contrary, the immunostaining was observed mainly located in the plasmatic membrane of malignant cells. However, Schmid et al. reported a cytoplasmatic and membranous staining of EGFR in SCLC [33]. Additionally, we detected the expression of EGF in about 17% of tumors, although no correlation between the expression of EGFR and EGF was detected. Previously, Kaseda et al. published both no EGF binding activity in 6 SCLC using 125I-EGF joint to no EGFR amplification in those specimens tissues [34]. Nevertheless, the activity of the EGFR pathway in SCLC has been previously demonstrated [33]. In spite of the fact that our data is very small; the exploration of the potential use of both EGFR and EGF as target for SCLC immunotherapy could be of interest. In this way, experiments in order to evaluate the functionality of the EGF/EGFR system in SCLC are being planned in our laboratory.

5. Conclusions

In summary, we reported the tissue reactivity of ior egf/r3 Mab, the murine counterpart of nimotuzumab, in both SCLC and NSCLC. The anti-proliferative activity and the capacity to induce apoptosis of egf/r3 Mab in a NSCLC cell line after binding the extracellular domain of EGFR were also demonstrated. In addition, we showed the immunohistochemical recognition of two different anti-EGF ligand monoclonal antibodies as well as their correlation with the expression of EGFR. The dual expression of both EGF and EGFR support the potential use of passive and active immunotherapy against these molecules alone or combined with established modalities. Moreover, our data permit to consider the development of diagnostic kits using ior egf/r3 Mab and CB-EGF1 Mabs in order to a better selection of patients to nimotuzumab and CIMAVax-EGF treatments, respectively.

Conflict of Interests

The authors report no conflict of interests.

Authors’ Contribution

Charles E. Rengifo and Rancés Blanco authors contributed equally to this work.

Acknowledgments

The authors want to thank M. S. Carmen Viada, for the excellent assistance at statistical analysis as well as B. S. Idania Suarez López-Gavilán, for the editorial assistance. Financial support was provided by the Center of Molecular Immunology.

References

[1] K. Kaira, N. Oriuchi, N. Sunaga, T. Ishizuka, K. Shimizu, and N. Yamamoto, “A systemic review of PET and biology in lung cancer,” The American Journal of Translational Research, vol. 3, no. 4, pp. 383–391, 2011.
[2] G. Giaccone and P. A. Zucali, “Src as a potential therapeutic target in non-small-cell lung cancer,” Annals of Oncology, vol. 19, no. 7, pp. 1219–1223, 2008.
[3] G. Bethune, D. Bethune, N. Ridgway, and Z. Xu, “Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update,” Journal of Thoracic Disease, vol. 2, pp. 48–51, 2010.
[4] P. K. Koh, C. Faire-Finn, F. H. Blackhall, and D. De Ruyscher, “Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy,” Cancer Treatment Reviews, vol. 38, no. 6, pp. 626–640, 2012.
[5] M. Takeda, I. Okamoto, Y. Nishimura, and K. N. Nimotuzumab, “A novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer,” Lung Cancer, vol. 2, pp. 59–67, 2011.
[6] B. García, E. Neninger, A. de la Torre et al., “Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine,” Clinical Cancer Research, vol. 14, no. 3, pp. 840–846, 2008.
[7] E. N. Vinageras, A. de la Torre, M. O. Rodriguez et al., “Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 9, pp. 1452–1458, 2008.
[8] C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris, and R. Pérez, “Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity,” Immunotechnology, vol. 3, no. 1, pp. 71–81, 1997.
I. Jannink, P. J. van Diest, and J. P. A. Baak, "Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium," Human Pathology, vol. 26, no. 10, pp. 1086–1092, 1995.

J. Vansteenkiste, C. Doms, and P. de Leyn, "Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging," Annals of Oncology, vol. 21, supplement 7, pp. 189–195, 2010.

C. A. Uyl-de Groot, J. McDonnell, H. J. M. Groen, D. Radice, and G. ten Velde, "Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small cell lung cancer: results of a Markov chain model," EJHP-S, vol. 11, no. 2, pp. 37–41, 2005.

P. Wheatley-Price and F. A. Shepherd, "Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes," Current Opinion in Oncology, vol. 20, no. 2, pp. 162–175, 2008.

G. V. Scagliotti, G. Selvaggi, S. Novello, and F. R. Hirsch, "The biology of epidermal growth factor receptor in lung cancer," Clinical Cancer Research, vol. 10, no. 12, article 4227s, 2004.

W. K. Boland and G. Bebb, "Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity," Expert Opinion on Biological Therapy, vol. 9, no. 9, pp. 1199–1206, 2009.

M. Cedeño-Arias, C. E. Rengifo, Y. R. Batista, E. R. Calzado, and T. Rodriguez, "Immunohistochemical evaluation of H-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor," Applied Immunohistochemistry and Molecular Morphology, vol. 15, no. 2, pp. 213–219, 2007.

M. Ramos, N. Rodriguez, J. P. Oliva et al., "99mTc-labeled anti-human epidermal growth factor receptor antibody in patients with tumors of epithelial origin: clinical trials safety and diagnostic efficacy," Journal of Nuclear Medicine, vol. 40, no. 5, pp. 768–775, 1999.

J. R. Grandis, M. F. Melhem, E. L. Barnes, and D. J. Tewardy, "Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck," Cancer, vol. 78, no. 6, pp. 1284–1292, 1996.

R. I. Nicholson, J. M. W. Gee, and M. E. Harper, "EGFR and cancer prognosis," European Journal of Cancer, vol. 37, supplement 4, pp. S9–S15, 2001.

T. Crombet-Ramos, J. Rak, R. Pérez, and A. Viloria-Petit, "Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: a humanized anti-EGFR antibody," International Journal of Cancer, vol. 101, no. 6, pp. 567–575, 2002.

A. Zhiquiang, "Antibody therapeutics—a mini review," Trends in Bio/Pharmaceutical Industry, vol. 2, pp. 24–29, 2008.

H. J. Choi, J. H. Sohn, C. G. Lee et al., "A phase I study of nimotuzumab in combination with radiotherapy in stages IIIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results," Lung Cancer, vol. 71, no. 1, pp. 55–59, 2011.

H.-Q. Wang, Y. Ren, Z.-Z. Qian et al., "Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer," Thoracic Cancer, vol. 3, no. 1, pp. 72–78, 2012.

G. Selvaggi, S. Novello, V. Torri et al., "Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer," Annals of Oncology, vol. 15, no. 1, pp. 28–32, 2004.

C. J. Piyathilake, A. R. Frost, U. Manne et al., "Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung," Clinical Cancer Research, vol. 8, no. 3, pp. 734–744, 2002.

X. Zhao, W. Dai, H. Zhu et al., "Epidermal growth factor (EGF) induces apoptosis in a transfected cell line expressing EGF receptor on its membrane," Cell Biology International, vol. 30, no. 8, pp. 653–658, 2006.

V. Rusch, D. Klimstra, E. Venkatraman, P. W. T. Pisters, J. Langenfeld, and E. Dmitrovsky, "Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression," Clinical Cancer Research, vol. 3, no. 4, pp. 515–522, 1997.

A. Viloria-Petit and E. Rengifo-Calzado, "Antiepidermal growth factor receptor antibody: immunohistochemistry," in Handbook of Immunohistochemistry and in Situ Hybridization Of Human Carcinomas, M. A. Hayat, Ed., vol. 3, pp. 79–101, Elsevier Academic Press, San Diego, Calif, USA, 2005.

A. F. Gazdar and J. D. Minna, "Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops," Cancer Prevention Research, vol. 1, no. 3, pp. 156–160, 2008.

F. R. Hirsch, G. V. Scagliotti, C. J. Langer, M. Varella-Garcia, and W. A. Franklin, "Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies," Lung Cancer, vol. 41, supplement 1, pp. S29–S42, 2003.